Single-cell sequencing of 15 patients with mantle cell lymphoma (MCL) receiving combined BTK inhibitor and CAR-T therapy revealed the importance of the HSP90-MYC-CDK9 axis in this treatment strategy [78]. Here, MYC is linked to mantle cell lymphoma.